scr.zacks.com 111 North Canal Street, Chicago, IL (ACAD-NASDAQ) NOTE ZACKS ESTIMATES
|
|
- Franklin French
- 5 years ago
- Views:
Transcription
1 Small-Cap Research November 27, 2012 Jason Napodano, CFA scr.zacks.com 111 North Canal Street, Chicago, IL Acadia Pharmaceuticals, Inc. (ACAD-NASDAQ) ACAD: Phase 3 PDP Hits, and it s a Homerun for Pimavanserin! Current Recommendation Neutral Prior Recommendation Outperform Date of Last Change 08/05/2008 Current Price (11/27/12) $5.72 Target Price $6.00 SUMMARY DATA 52-Week High $ Week Low $0.95 One-Year Return (%) Beta 2.69 Average Daily Volume (sh) 1,674,971 Shares Outstanding (mil) 53 Market Capitalization ($mil) $122 Short Interest Ratio (days) 0.79 Institutional Ownership (%) 11 Insider Ownership (%) 0 Annual Cash Dividend $0.00 Dividend Yield (%) Yr. Historical Growth Rates Sales (%) 18.0 Earnings Per Share (%) Dividend (%) P/E using TTM EPS P/E using 2012 Estimate P/E using 2013 Estimate NOTE On November 27, 2012, Acadia Pharmaceuticals announced the successful results from its pivotal phase 3 trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson s disease psychosis (PDP). Although only topline results, the data looks like a homerun for management. We are leaving our rating at Neutral because the stock is so near our $6 target. We would not chase the stock here. Pimavanserin is still three years from commercialization. However, if we are correct in our assumption that Acadia does raise capital via the ATM or a secondary in the near-term, investors could get a good buying opportunity. This is clearly a stock we like. The single biggest catalyst for the shares is the signing of a deal in We recommend using pullbacks to establish a position prior to that event. Risk Level Type of Stock Industry ZACKS ESTIMATES Above Average Small-Growth Med-Biomed/Gene Revenue (In millions of $) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) A 0.5 A 0.6 A 0.6 A 2.1 A A 0.6 A 3.5 A 0.3 E 4.8 E E E Earnings per Share (EPS is operating earnings before non-recurring items) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) $0.12 A -$0.12 A -$0.10 A -$0.10 A -$0.44 A $0.12 A -$0.10 A -$0.04 A -$0.08 E -$0.35 E $0.21 E $0.20 E Copyright 2012, Zacks Investment Research. All Rights Reserved.
2 WHAT S NEW Phase Study In PDP Hits Primary & Secondary Endpoints On November 27, 2012, Acadia Pharmaceuticals announced the successful results from its pivotal phase 3 trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson s disease psychosis (PDP). Although only top-line results, the data looks like a homerun for management. A Little Background Info PDP is a debilitating psychiatric disorder that occurs in up to 50% of patients with Parkinson's disease. In the U.S., we estimate this is 500,000 patients. PDP is characterized by the presence of hallucinations and delusions. Hallucinations are most common and are often visual, but may also include somatic or other sensory phenomena. Delusions commonly involve paranoia, and can be profoundly disturbing and debilitating. PDP represents a major inflection point in the course of Parkinson's disease progression, and is the number one driver of why patients enter nursing homes or long-term care facilities. PDP is associated with increased caregiver burden and increased mortality. Currently, there are no therapies approved to treat Parkinson's disease psychosis. Acadia s pimavanserin is a potent and selective 5-HT2A inverse agonist. The drug is designed to regulate the optimal combination of dopamine (D2) receptor blockade and 5-HT2A inverse agonism, thus reducing symptoms of PDP without impairing motor function, a major side effect of current off-label antipsychotic use, and thereby significantly improving the quality of life for patients with the disease. The Trial Design The pivotal phase 3 trial, referred to as the -020 Study, was a multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with PDP. A total of 199 patients were enrolled in the study and randomized on a one-to-one basis to receive either 40 mg of pimavanserin or placebo once-daily for six weeks, following a two-week screening period including brief psycho-social therapy designed to draw forward placebo response. The trial enrolled patients only in the U.S. with severe PDP as defined by the neuropsychiatric inventory (NPI) scale (NPI score > 6). Patients also received stable doses of their existing anti-parkinson s therapy throughout the study. Primary Endpoint The primary endpoint of the -020 Study was antipsychotic efficacy as measured using the SAPS PD scale, which consists of 9- items from the hallucinations and delusions domains of the Scale for the Assessment of Positive Symptoms (SAPS). Pimavanserin met the primary endpoint in the phase 3 trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). SAPS-PD Pima- Placebo (n=95) (n=90) Baseline Day P-Value Zacks Investment Research Page 2 scr.zacks.com
3 Secondary Endpoints Motoric tolerability was a key secondary endpoint in the study and was measured using Parts-II and -III of the Unified Parkinson s Disease Rating Scale (UPDRS). After 43 days on treatment, patients taking pimavanserin experienced a change in UPDRS vs for the placebo. The results show that pimavanserin is non-inferior to the placebo (i.e. has no negative effects on motor function). We believe this is extremely important in the marketing of the drug because the leading off-label antipsychotic therapies, clozapine and quetiapine, negatively impact motor function and carry significant side effects such as increased parkinsonism, orthostasis, sedation, confusion, and drooling. Clozapine also requires weekly phlebotomy to monitor for potential agranulocytosis. Another secondary endpoint was Clinical Global Impression Improvement (CGI-I), which was highly statistically significant in favor of pimavanserin (p=0.001). Management also assessed a number of exploratory endpoints, all which demonstrated strong support for the antipsychotic efficacy of pimavanserin. One secondary endpoint was the Caregiver Burden Scale, an assessment done by the caregiver to provide a quantitative assessment of burden associated with the patient s functional/behavioral impairments, the circumstances of at-home care, as well as the caregiver s health, social life and interpersonal relations. Results were statistically significant (p=0.012). Acadia also assessed the impact on sleep using the SCOPA-sleep scale, which was designed to enable the investigator to evaluate nighttime sleep and daytime wakefulness in Parkinson s patients. Pimavanserin demonstrated significant improvements on both nighttime sleep (p=0.045) and daytime wakefulness (p=0.012) on SCOPA. Safety & Tolerability Acadia reported that pimavanserin was safe and well tolerated in the -020 Study. Based on a preliminary safety analysis, the most common adverse events were urinary tract infection (11.7% placebo vs. 13.5% pimavanserin) and falls (8.5% placebo vs. 10.6% pimavanserin). Adverse events were generally characterized as mild to moderate in nature. The only serious adverse events (SAE) that occurred in more than one patient were urinary tract infection (1 placebo vs. 3 pimavanserin) and psychotic disorder (2 pimavanserin). In the past we ve noted that 90% of the patients who completed the -020 Study elected to roll over into the ongoing open-label safety extension study, dubbed Patients were only eligible to participate in the extension study if the treating investigator also deemed them to be likely to benefit from continued treatment with pimavanserin. Pimavanserin looks like a safe and highly tolerable drug. Safety and tolerability data from the previous phase 3 studies, -012 and -014, are consistent with the findings from We would like some additional clarity on the two cases of psychotic disorder seen in the pimavanserin arm during -020, but as of now this remains on the only potential safety blemish on an otherwise very clean profile. Our Analysis Of The Data and Market Opportunity As noted above, we think these data are a Homerun for management. The results are highly statistically significant and the safety profile is very clean. We even learned about new potential marketing advantages for the drug, including highly statistically significant results on the Caregiver Burden scale and improvements in both nighttime sleep and daytime wakefulness. Dr. Stuart Isaacson, M.D., Associate Professor of Neurology, FIU College of Medicine, Miami, FL and Director of the Parkinson s Disease and Movement Disorders Center of Boca Raton, FL called the results a game changer on Acadia s conference call. Zacks Investment Research Page 3 scr.zacks.com
4 We ve noted in the past, PDP is a high unmet medical need and a debilitating effect on patients with Parkinson s disease. There truly are no effective medications for patients with PDP. Clinical management of PDP starts with primary prevention; but PDP progresses rapidly as the Parkinson patient deteriorates, and often ends with the undesirable use of atypical antipsychotics. Prescription tracking data shows that half of Parkinson's disease patients are taking antipsychotic agents to control PDP, which may lead to worsening Parkinson's symptoms. A paper published by Dr. Laura Marsh, MD, in Primary Psychiatry (2005;12(7):56-62) does an outstanding job of highlighting the issues with the current treatment paradigm for PDP. From the paper: Atypical antipsychotics with a low potential for inducing parkinsonism (rigidity, bradykinesia, and tremor) are used in PD. Among those currently available (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole), only quetiapine and clozapine are consistently recommended. Clozapine is currently the gold standard of antipsychotic agents in PD given its demonstrated safety and efficacy in controlled trials without worsening parkinsonian symptoms. Sedation or confusion can occur at low doses in this fragile population and most patients respond to <50 mg/day, though some require higher doses or an additional low dose in the mornings. The most common side effects are sedation, orthostasis, confusion, and drooling. Motor fluctuations worsen in some patients, but dystonia, dyskinesias, and tremor can improve. Weekly phlebotomy is required to monitor for potential agranulocytosis. Any inconvenience of this is offset by therapeutic benefits. Quetiapine is a common first choice because it can be used without the risk of agranulocytosis and weekly blood monitoring. However, quetiapine has not been subject to controlled trials. Its safety and efficacy profile in open-label studies is favorable, but inadequate symptom control or increased parkinsonism or motor fluctuations can occur. Lower doses are used initially because patients with hypotension or orthostasis may not tolerate higher doses. Sedation and confusion are common side effects, but a recent open-label study showed improved cognitive functioning on quetiapine. For the reasons outlined above, we see pimavanserin as serving a fairly high unmet need. We know of no other drug under late-stage development for PDP, and believe that pimavanserin should have meaningful market exclusivity upon launch. As such, we think that Acadia and its commercialization partner could capture up to a third of the market. At a price similar to antipsychotics, pimavanserin offers a $400 million U.S. opportunity. $378 Million = 1 Million PD patients x 50% with Psychosis x 33% Penetration x $2,500 per year. Label Expansion Key To Sales Upside... Beyond the initial indication in PDP, we believe pimavanserin has potential utility in Alzheimer's disease psychosis (ADP), a disease with similar manifestations to PDP. The ADP market plays out in similar fashion to PDP, only potentially five times as large. Statistics show the number of American's living with Alzheimer's disease to be roughly 5.4 million, roughly 50% of which will develop some form of psychosis as the disease progresses. In July 2012, management reported promising mechanistic data with pimavanserin in a preclinical rodent model of the disease. This data was published in Behavioral Pharmacology (Price et al., Pimavanserin, a 5-HT2A Receptor Inverse Agonist, Reverses Psychosis-like Behaviors in a Rodent Model of Alzheimer s Disease, ) in July If pimavanserin is a $400 million drug in the U.S. for PDP, with similar data in ADP, it s a blockbuster drug. Zacks Investment Research Page 4 scr.zacks.com
5 ...And So is Partnering Now that the top-line data from -020 has been released, and the stock is up roughly 150% as of the writing of this report, management has some flexibility on when to partner the drug. Acadia exited the third quarter 2012 with approximately $23.1 million in cash, cash equivalents, and short-term investments. We find this to be sufficient to fund operations into the second half of Acadia burned $4.8 million in the third quarter 2012 and $15.3 million during the first nine months of the year. We remind investors that Acadia has an At-the-Market Issuance Sales Agreement ( ATM ) active with MLV & Co. LLC. During the third quarter 2012, Acadia sold approximately 3.49 million shares of common stock pursuant to its ATM at approximately $2.00 per share, resulting in net proceeds (after 3% fees to MLV) of roughly $6.8 million. The ATM allows for up to $20 million in sales, leaving $14.2 million yet untapped. We expect management to raise this $14.2 million shortly, as the cost of the confirmatory phase 3 program, dubbed -021, is an estimated $15 million. Given the current stock price, this $14.2 million can be raised by issuing about 2.5 million shares, or around 4.5% dilution to the current basic share count of 56.6 million. We note there are an additional 4.4 million warrants outstanding with an exercise price of $1.38 per share that could bring in another $6.1 million to the company. Ultimately, Acadia needs to partner pimavanserin. The drug and market opportunity are too big to go alone, and investors would benefit from having a big pharma partner help Acadia navigate the new drug application (NDA) filing process and potential FDA curve balls around chemistry, manufacturing and controls (CMC). Plus, Acadia is focusing only on North American right now with pimavanserin. There is obviously meaningful sales opportunity for the drug in Europe and Asia. Acadia needs a partners help to enter these markets. Now that the results from the -020 trial are out and positive, we suspect that management will have little trouble finding a development and commercialization partner for the drug. The question remains, when to partner? We remind investors that Acadia did previously have a deal to commercialize pimavanserin with Biovail. Biovail paid Acadia $30 million upfront with the potential for $365 million and 15-20% royalties on sales back in May 2009 prephase 3. It s clearly worth a lot more now. With respect to the -021 Study, we expect many of the same sites will be used from Management may look to expand more in Canada for -021, but we do not expect any significant enrollment outside of North America. On today s conference call, Executive Vice President of Development, Roger G. Mills, M.D. said, We don t plan to mess with a winning team. That s smart. Now is not the time to get cute. The trial worked because Acadia enrolled PDP patients with severe psychosis and found ways to mitigate placebo response. If the product is eventually approved, we expect sizable use in earlier-stage PDP patients. Dr. Isaacson noted on the call that as a treating physician, if there is a drug that works then he would not wait for symptoms to materialize in severe form. We suspect most caregivers will agree, and use pimavanserin far earlier in the real world setting than the strict entry criteria instituted in the -020 study. The Caregiver Burden Scale management assessed in the -020 Study was brilliant pure marketing ammunition. That being said, we think Acadia will leave much of the label expansion work into APD and schizophrenia for the partner. Management sees pimavanserin as a pipeline-product. Much of the back-end potential from the Biovail deal was based on expanding the label into ADP and schizophrenia. We think Acadia will be looking for a similar deal in 2013, but in the near-term will push forward with the -021 Study alone. That means, do not expect a deal to be announced in the next month. Instead, expect Acadia to tap its ATM or even do a secondary offering. Zacks Investment Research Page 5 scr.zacks.com
6 Our Model Says $6 Is Fair Pre-data we believed the stock was worth around $2.50 per share. We ve now made some pretty significant changes to our model post-data. We ve dramatically reduced the discount rate (risk) in our DCF model, and are now using a discount rate of 13.8% (risk free of 1.75% + equity risk premium of 6.0% x 100% firm adjustment). We have also adjusted up slightly our peak sales estimate for pimavanserin in PDP, from $312 million in the U.S. based on 25% penetration to $378 million in the U.S. based on 33% penetration. The data from -020 are that good. On a global basis, with positive data in ADP that matches what we got today in PDP, pimavanserin is a $2+ billion drug. We also assume that Acadia does partner the drug in 2013, and lands $50 million upfront and up to $500 million backend potential with 20% royalty on sales. We are leaving our rating at Neutral because the stock is so near our $6 target. We would not chase the stock here. Pimavanserin is still three years from commercialization. However, if we are correct in our assumption that Acadia does raise capital via the ATM or a secondary in the near-term, investors could get a good buying opportunity. This is clearly a stock we like. The single biggest catalyst for the shares is the signing of a deal in We recommend using pullbacks to establish a position prior to that event. Our DCF model is below: Zacks Investment Research Page 6 scr.zacks.com
7 PROJECTED FINANCIALS Acadia Pharmaceuticals Inc. Income Statement Acadia Pharma 2011 A Q1 A Q2 A Q3 A Q4 E 2012 E 2013 E 2014 E 2015 E pimavanserin (NA Sales) $0 $0 $0 $0 $0 $0 $0 $0 $0 pimavanserin (Ex-NA) $0 $0 $0 $0 $0 $0 $0 $0 $0 pimavanserin (royalty) $0 $0 $0 $0 $0 $0 $0 $0 $0 YOY Growth Collaborations $2.1 $0.5 $0.6 $3.5 $0.3 $4.8 $10.0 $10.0 $15.0 YOY Growth -95.1% 3.4% 30.2% 495.5% -49.0% 133.5% 107.2% 0.0% 50.0% Total Revenues $2.1 $0.5 $0.6 $3.5 $0.3 $4.8 $10.0 $10.0 $15.0 YOY Growth -95.1% 3.4% 30.2% 495.5% -49.0% 133.5% 107.2% 0.0% 50.0% Cost of Goods Sold $0 $0 $0 $0 $0 $0 $0 $0 $0 Gross Margin 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% SG&A $6.5 $1.4 $1.2 $1.2 $1.3 $5.1 $6.0 $6.5 $6.5 % SG&A 315.6% 308.0% 205.7% 33.2% 433.3% 105.1% 60.0% 65.0% 43.3% R&D $16.8 $4.9 $4.3 $4.2 $3.5 $16.9 $15.0 $15.0 $15.0 % R&D 812.6% % 720.9% 122.0% % 351.0% 150.0% 150.0% 100.0% Stock Options $1.6 $0.4 $0.5 $0.5 $0.4 $1.8 $1.8 $2.0 $2.0 % Stock Options 77.3% 91.8% 79.8% 14.0% 133.3% 36.9% 18.0% 20.0% 13.3% Operating Income ($22.9) ($6.2) ($5.4) ($2.4) ($4.9) ($19.0) ($12.8) ($13.5) ($8.5) Operating Margin Interest & Other Income $0.1 $0.0 $0.0 $0.0 $0.1 $0.1 $0.2 $0.2 $0.2 Pre-Tax Income ($22.8) ($6.2) ($5.4) ($2.4) ($4.8) ($18.8) $12.6 $13.3 $8.3 Taxes + Other $0 $0 $0 $0 $0 $0 $0 $0 $0 Tax Rate 0% 0% 0% 0% 0% 0% 0% 0% 0% Net Income ($22.8) ($6.2) ($5.4) ($2.4) ($4.8) ($18.8) ($12.6) ($13.3) ($8.3) YOY Growth Net Margin Reported EPS ($0.44) ($0.12) ($0.10) ($0.04) ($0.08) ($0.35) ($0.21) ($0.20) ($0.12) YOY Growth Diluted Shares Out Source: Zacks Investment Research Inc. Jason Napodano, CFA Copyright 2012, Zacks Investment Research. All Rights Reserved.
8 Zacks Investment Research Page 8 scr.zacks.com
9 HISTORICAL ZACKS RECOMMENDATIONS DISCLOSURES The following disclosures relate to relationships between Zacks Investment Research ( ZIR ) and Zacks Small-Cap Research ( Zacks SCR ) and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe. ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management. Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters. The current distribution of Zacks Ratings is as follows on the 1013 companies covered: Buy/Outperform- 14.2%, Hold/Neutral- 77.9%, Sell/Underperform 7.4%. Data is as of midnight on the business day immediately prior to this publication. Copyright 2012, Zacks Investment Research. All Rights Reserved.
Zacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationSmall-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014
Small-Cap Research December 17, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Auspex Pharmaceuticals Inc. ASPX SD-809 Hits
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationSmall-Cap Research. Neurocrine Biosciences, Inc. (NBIX-NASDAQ) NBIX: KINECT-2 Hits, Shares Soar! UPDATE SUMMARY DATA ZACKS ESTIMATES
Small-Cap Research January 6, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Neurocrine Biosciences, Inc. NBIX: KINECT-2 Hits, Shares
More informationSmall-Cap Research. Delmar Pharma (DMPI-OTCQB)
Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal
More informationSmall-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK
Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:
More informationSmall-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK
Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase
More informationSmall-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA
Small-Cap Research March 27, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (DARA-NASDAQ) OUTLOOK ZACKS ESTIMATES
Small-Cap Research November 18, 2011 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 DARA BioSciences, Inc. (DARA-NASDAQ) DARA: Pipeline Moving
More informationPimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs
Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements.
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (ASTM-NASDAQ) UPDATE ZACKS ESTIMATES
Small-Cap Research March 12, 2012 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Aastrom Biosciences, Inc. (ASTM-NASDAQ) ASTM: Financing Complete,
More information(GALE-NASDAQ) OUTLOOK
Small-Cap Research November 7, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Galena Biopharma Inc. Galena: Reported sales from Abstral ahead
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (DEPO-NASDAQ) UPDATE ZACKS ESTIMATES
Small-Cap Research December 19, 2013 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Depomed Inc. (DEPO-NASDAQ) DEPO: Another Fine Deal For
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationZacks Small-Cap Research Sponsored Impartial - Comprehensive
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 27, 2018 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics (ATOS-NASDAQ)
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES
Small-Cap Research August 26, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Uplist to Nasdaq
More informationZacks Small-Cap Research
Zacks Small-Cap Research October 26, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 CytoSorbents Corporation (CTSO-NASDAQ) CTSO: Additional
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research August 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Expecting overall survival data
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL UPDATE ZACKS ESTIMATES
Small-Cap Research November 14, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Matinas BioPharma Holdings, Inc. (MTNB-OTCQB)
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (PRTX-OTCQB) UPDATE ZACKS ESTIMATES
Small-Cap Research June 17, 2014 Jason Napodano, CFA David Bautz, PhD 312-265-9421 / jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Protalex, Inc. PRTX: Analysis
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (ANTB-OTC) Update ZACKS ESTIMATES
Small-Cap Research August 17, 2015 Nisha Hirani, MD 312-265-9442 / nhirani@zacks.com David Bautz, PhD 312-265-9471 / dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (ANTB-OTC) Update ZACKS ESTIMATES
Small-Cap Research May 15, 2015 Jason Napodano, CFA Nisha Hirani, MD 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 AntriaBio, Inc. (ANTB-OTC) ANTB:
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (ADDXF-OTC) UPDATE ZACKS ESTIMATES
Small-Cap Research February 8, 2013 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Addex Therapeutics Ltd. (ADDXF-OTC) ADXN: Refocusing Resources
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES
Small-Cap Research February 24, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Update on
More informationOrexigen Therapeutics, Inc.
February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA
More informationMedivation, Inc. (MDVN-NASDAQ)
March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY
More informationSmall-Cap Research. Soligenix Inc. (SNGX-OTCBB) OUTLOOK
Small-Cap Research January 04, 2016 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Soligenix Inc. SNGX: Positive data reported from Phase II of SGX942
More informationSmall-Cap Research. Verisante Technology Inc. (V.VRS) V.VRS: Big Jump In Revenue, Intro of MSI Camera OUTLOOK SUMMARY DATA ZACKS ESTIMATES
December 2, 2013 Small-Cap Research Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Verisante Technology Inc. (V.VRS) V.VRS: Big Jump In Revenue,
More informationt Small-Cap Research Tonix Pharmaceuticals Holding Corp. (TNXP-NASDAQ) TNXP: Phase 3 Study of TNX-102 SL in PTSD to Initiate in 1Q17 OUTLOOK
t Small-Cap Research November 29, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Tonix Pharmaceuticals Holding Corp. (TNXP-NASDAQ) TNXP: Phase
More informationSmall-Cap Research. Durect Corp (DRRX-NASDAQ) DRRX: Zacks Company Report OUTLOOK SUMMARY DATA ZACKS ESTIMATES
Small-Cap Research August 2, 2016 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Durect Corp (DRRX-NASDAQ) DRRX: Zacks Company Report DRRX: Remoxy approved
More informationSmall-Cap Research. Lion Biotech (LBIO-OTC)
Small-Cap Research June 25, 2014 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Lion Biotech (LBIO-OTC) LBIO: Balance sheet remains strong, the appointment
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (GNSZ - OTC) UPDATE ZACKS ESTIMATES
Small-Cap Research November 23, 2015 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 GenSpera, Inc. (GNSZ - OTC) GNSZ: Mipsagargin Shows
More informationSmall-Cap Research. Neurocrine Biosciences, Inc. (NBIX - Nasdaq) NBIX: NDA for Valbenazine in Tardive Dyskinesia to be Filed in 2016 SUMMARY DATA
Small-Cap Research May 9, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Neurocrine Biosciences, Inc. (NBIX - Nasdaq) NBIX: NDA for
More informationZacks Small-Cap Research Sponsored Impartial - Comprehensive
Zacks Small-Cap Research Sponsored Impartial - Comprehensive January 24, 2019 Brian Marckx, CFA 312-265-9474 bmarckx@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics (ATOS-NASDAQ)
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive March 21, 2018 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Aevi Genomic Medicine
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive May 15, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals, Inc.
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationSmall-Cap Research. GeoVax Labs Inc. (GOVX-OTC) GOVX: On track to advance Ebola & HIV Programs UPDATE SUMMARY DATA ZACKS ESTIMATES
Small-Cap Research August 12, 2015 Grant Zeng, CFA Nisha Hirani, MD 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 GeoVax Labs Inc. (GOVX-OTC) GOVX: On track to advance
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: Large U.S. Study Comes Cheap and Could Support Eventual Asymptomatic FDA Filing OUTLOOK
Small-Cap Research July 31, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: Large U.S. Study Comes Cheap
More information(GALE-NASDAQ) OUTLOOK
Small-Cap Research March 19, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Galena Biopharma Inc. Galena: Acquisition of Abstral transforms GALE
More informationscr.zacks.com 10 S. Riverside Dr, Suite 1600, Chicago, IL UPDATE ZACKS ESTIMATES
Small-Cap Research February 29, 2016 Anita Dushyanth, PhD Brian Marckx, CFA 312-265-9434 / adushyanth@zacks.com scr.zacks.com 10 S. Riverside Dr, Suite 1600, Chicago, IL 60606 Cynapsus Therapeutics Inc.
More information22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationscr.zacks.com 10 S. Riverside Dr, Suite 1600, Chicago, IL UPDATE ZACKS ESTIMATES
Small-Cap Research August 20, 2015 Anita Dushyanth, PhD Brian Marckx, CFA 312-265-9434 / adushyanth@zacks.com scr.zacks.com 10 S. Riverside Dr, Suite 1600, Chicago, IL 60606 Cynapsus Therapeutics Inc.
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (DARA-NASDAQ) ZACKS ESTIMATES
Small Cap Research September 14, 2012 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 DARA BioSciences, Inc. (DARA-NASDAQ) DARA: Get On Board
More informationSmall-Cap Research. OncoSec Medical (ONCS-NASDAQ) OUTLOOK
Small-Cap Research April 26, 2016 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 OncoSec Medical ONCS: Unique electroporation delivery technology for
More informationSmall-Cap Research. scr.zacks.com 10 S. Riverside Plaza, Chicago, IL ZACKS ESTIMATES
Small-Cap Research August 16, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Viking Therapeutics, Inc. VKTX: Data From Phase 2 Studies of VK2809
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationSmall-Cap Research. OncoSec Medical (ONCS-NASDAQ) OUTLOOK
Small-Cap Research March 3, 2016 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 OncoSec Medical ONCS: Unique electroporation delivery technology for
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationSmall-Cap Research. Atossa Genetics (ATOS-NASDAQ) OUTLOOK
Small-Cap Research December 24, 2014 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics ATOS: Focused pure play breast care company with
More informationAltria Group Inc (MO-NYSE)
March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00
More informationPerrigo Company plc (PRGO-NYSE)
March 20, 2015 Perrigo Company plc (PRGO-NYSE) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 09/02/2012 Current Price (03/19/15) $170.37 Target Price $179.00 SUMMARY
More informationSmall-Cap Research. Cynapsus Therapeutics (CYNA-NASDAQ)
Small-Cap Research July 21, 2016 Anita Dushyanth, PhD 312-265-9434/adushyanth@zacks.com Brian Marckx, CFA 312-265-9474/bmarckx@zacks.com Cynapsus Therapeutics (CYNA-NASDAQ) CYNA: Announces Positive Results
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Stamford Ft. Lauderdale EQUITY RESEARCH Company Report Mast Therapeutics (MSTX - $ 0.50) Vepoloxamer Pre-clinical Data to Be Presented at Sickle Cell Disease
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationSmall-Cap Research. Cynapsus Therapeutics (CYNA-NASDAQ) CYNA: Business Update OUTLOOK
Small-Cap Research July 6, 2016 Anita Dushyanth, PhD 312-265-9434/adushyanth@zacks.com Brian Marckx, CFA 312-265-9474/bmarckx@zacks.com Cynapsus Therapeutics CYNA: Business Update (CYNA-NASDAQ) OUTLOOK
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationSmall-Cap Research. GeneNews Limited (GEN-TO, GNWSF-OTC)
Small-Cap Research June 5, 2014 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 GeneNews Limited (GEN-TO, GNWSF-OTC) GEN.TO: 1Q14 revenue from IDL is
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationSmall-Cap Research. Medgenics Inc (MDGN-NASDAQ) MDGN: Eagerly Awaiting NFC-1 ADHD Phase 2/3 Data, Now Expected Q OUTLOOK SUMMARY DATA
Small-Cap Research December 8, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Medgenics Inc (MDGN-NASDAQ) MDGN: Eagerly Awaiting NFC-1
More informationNovo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationNewron announces 2018 financial results and provides outlook for 2019
Newron announces 2018 financial results and provides outlook for 2019 Milan, Italy, March 5, 2019 Newron Pharmaceuticals S.p.A. ( Newron ), a biopharmaceutical company focused on the development of novel
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationZacks Small-Cap Research Sponsored Impartial - Comprehensive
Zacks Small-Cap Research Sponsored Impartial - Comprehensive November 16, 2018 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Durect Corp (DRRX-NASDAQ)
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationMYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017
Mental Health November 28, 2017 MYnd Analytics, Inc. OTC MYND We believe MYnd Analytics is commercializing a very valuable predictive technology in a field of medicine, mental disorders, where desicisions
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationEquity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape
Member FINRA and SIPC Equity Research November 17, 2017 Healthcare Industry Update Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape Conclusions We hosted a key opinion leader
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationMDxHealth. Acceleration of payor coverage ConfirmMDx. Research Note.
Research Note MDxHealth Acceleration of payor coverage ConfirmMDx Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More information(LO-NYSE) SUMMARY. Risk Level *
February 12, 2015 Lorillard Inc. (LO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 05/22/2012 Current Price (02/11/15) $67.55 Target Price $71.00
More informationWntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationSmall-Cap Research. Delmar Pharma (DMPI-OTCQB)
Small-Cap Research July 2, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Clinical/commercial stage biopharmaceutical
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationMDxHealth. AssureMDx leaves competition behind. Research Note.
Research Note MDxHealth AssureMDx leaves competition behind Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date:
More informationInvestor Presentation Post-Interim Results Update. September 2011
Investor Presentation Post-Interim Results Update September 2011 Disclaimer This presentation contains general information about the company s activities current as at 2 September 2011. It is provided
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More information